Q32

Q32 Bio and Homology Medicines Announce Merger Agreement

Retrieved on: 
Thursday, November 16, 2023
Bristol Myers Squibb, ANCA, AA, Clinical trial, Patient, Alopecia areata, Atopic dermatitis, Therapy, Q32, OrbiMed, Trial of the century, TSLP, IL-7, System, Autoimmunity, AAV, OUP, Vaccine, Pharmaceutical industry

WALTHAM, Mass. and BEDFORD, Mass., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Q32 Bio Inc., a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Homology Medicines, Inc. (Nasdaq: FIXX), today announced they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Q32 Bio’s wholly owned clinical development candidates for the treatment of autoimmune and inflammatory diseases. Upon completion of the merger, the combined company will operate as Q32 Bio, headquartered in Waltham, Massachusetts, and is expected to trade under the Nasdaq ticker symbol “QTTB”.

Key Points: 
  • and BEDFORD, Mass., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Q32 Bio Inc., a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Homology Medicines, Inc. (Nasdaq: FIXX), today announced they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.
  • The combined company will focus on advancing Q32 Bio’s wholly owned clinical development candidates for the treatment of autoimmune and inflammatory diseases.
  • Upon completion of the merger, the combined company will operate as Q32 Bio, headquartered in Waltham, Massachusetts, and is expected to trade under the Nasdaq ticker symbol “QTTB”.
  • “The proposed merger with Homology Medicines and concurrent private placement is expected to provide Q32 Bio with the capital to drive development of our autoimmune and inflammatory pipeline through multiple clinical milestones,” said Jodie Morrison, Chief Executive Officer of Q32 Bio.

Q32 Bio Appoints Adam Cutler as Chief Financial Officer

Retrieved on: 
Wednesday, July 7, 2021
Fifth Avenue, Fifth and Madison Avenues Line, Madison Avenue, Q32

CAMBRIDGE,Mass., July 7, 2021 /PRNewswire/ -- Q32 Bio , a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Adam Cutler as Chief Financial Officer.

Key Points: 
  • CAMBRIDGE,Mass., July 7, 2021 /PRNewswire/ -- Q32 Bio , a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Adam Cutler as Chief Financial Officer.
  • "We warmly welcome Adam to the Q32 Bio team as our Chief Financial Officer," said Mike Broxson, Chief Executive Officer of Q32 Bio.
  • "I'm very pleased to be joining Q32 Bio at this exciting stage of its development," said Mr. Cutler.
  • Prior to joining Q32 Bio, Mr. Cutler served as Chief Financial Officer of Molecular Templates.

Q32 Bio Launches to Develop Novel Therapeutics Targeting Regulators of Innate and Adaptive Immunity

Retrieved on: 
Wednesday, May 27, 2020
Immunology, Immunity, Immune system, Adaptive immune system, Autoimmunity, Q32

Q32 Bio was seeded and incubated by Atlas Venture with foundational science from renowned researchers in immunology Michael Holers, M.D.

Key Points: 
  • Q32 Bio was seeded and incubated by Atlas Venture with foundational science from renowned researchers in immunology Michael Holers, M.D.
  • "Q32 Bio has a preeminent team with expertise in both innate and adaptive immunity, a board of directors and scientific advisory board made up of leaders in our field, and a syndicate of blue-chip investors.
  • Shelia Violette, Ph.D., joined Q32 Bio from Atlas Venture, where she was Entrepreneur in Residence and initially co-led the formation of Q32 Bio.
  • Q32 Bio is a biotechnology company developing therapies targeting powerful regulators of the innate and adaptive immune systems, to re-balance immunity in severe autoimmune and inflammatory diseases.